Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Normalizing hepcidin predicts TMPRSS6 mutation status in patients with chronic iron deficiency.

Heeney MM, Guo D, De Falco L, Campagna DR, Olbina G, Kao PP, Schmitz-Abe K, Rahimov F, Gutschow P, Westerman K, Ostland V, Jackson T, Klaassen RE, Markianos K, Finberg KE, Iolascon A, Westerman M, London WB, Fleming MD.

Blood. 2018 Jun 12. pii: blood-2017-03-773028. doi: 10.1182/blood-2017-03-773028. [Epub ahead of print] No abstract available.

PMID:
29895660
2.

The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis Type 1.

Northman L, Morris M, Loucas C, Ross S, Muriel AC, Guo D, London WB, Manley P, Ullrich NJ.

J Pediatr Oncol Nurs. 2018 Jul/Aug;35(4):276-286. doi: 10.1177/1043454218765140. Epub 2018 Mar 30.

PMID:
29600747
3.

Nonmalignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children.

Huang JT, Song JS, Hawryluk EB, London WB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN.

J Am Acad Dermatol. 2018 Mar 26. pii: S0190-9622(18)30481-X. doi: 10.1016/j.jaad.2018.03.029. [Epub ahead of print]

PMID:
29588248
4.

Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.

Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D, Al-Sayegh H, London WB, Gallagher PG, Zanella A, Barcellini W.

Blood. 2018 May 17;131(20):2183-2192. doi: 10.1182/blood-2017-10-810796. Epub 2018 Mar 16.

PMID:
29549173
5.

Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, London WB, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K.

J Natl Cancer Inst. 2018 Mar 5. doi: 10.1093/jnci/djy022. [Epub ahead of print]

PMID:
29514301
6.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

7.

Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

de Alarcon PA, Matthay KK, London WB, Naranjo A, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL.

Lancet Child Adolesc Health. 2018 Jan;2(1):25-34. doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3.

PMID:
29376112
8.

Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.

Guenther LM, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE, Ecklund K, Janeway KA.

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26896. Epub 2017 Dec 18.

PMID:
29251406
9.

Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.

O'Neill AF, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, London WB, Garber JE, Diller L.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26822. Epub 2017 Oct 27.

PMID:
29077256
10.

Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.

Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM.

Clin Cancer Res. 2018 Jan 1;24(1):189-196. doi: 10.1158/1078-0432.CCR-17-1767. Epub 2017 Oct 2.

PMID:
28972044
11.

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

London WB, Bagatell R, Weigel BJ, Fox E, Guo D, Van Ryn C, Naranjo A, Park JR.

Cancer. 2017 Dec 15;123(24):4914-4923. doi: 10.1002/cncr.30934. Epub 2017 Sep 8. Review.

PMID:
28885700
12.

Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.

Marinoff AE, Ma C, Guo D, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, London WB, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P.

J Neurooncol. 2017 Oct;135(1):201-211. doi: 10.1007/s11060-017-2568-8. Epub 2017 Jul 21.

13.

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.

Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG.

Cancer. 2017 Nov 1;123(21):4224-4235. doi: 10.1002/cncr.30873. Epub 2017 Jul 11.

PMID:
28696504
14.

HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.

Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM.

Front Immunol. 2017 Jun 12;8:675. doi: 10.3389/fimmu.2017.00675. eCollection 2017.

15.

Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.

Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.

16.

Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.

J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. Review.

17.

Reply to J. Stenman et al.

La Quaglia MP, Haas-Kogan D, Park J, Kreissman SG, von Allmen D, Davidoff A, London WB, Khanna G.

J Clin Oncol. 2017 Jun 10;35(17):1966-1967. doi: 10.1200/JCO.2017.72.2777. Epub 2017 Apr 19. No abstract available.

PMID:
28422554
18.

Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.

Song JS, London WB, Hawryluk EB, Guo D, Sridharan M, Fisher DE, Lehmann LE, Duncan CN, Huang JT.

Bone Marrow Transplant. 2017 Jul;52(7):989-997. doi: 10.1038/bmt.2017.57. Epub 2017 Apr 3.

PMID:
28368380
19.

Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation.

Li R, Polishchuk A, DuBois S, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay KK, London WB, Marcus KJ.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):270-277. doi: 10.1016/j.ijrobp.2016.10.047. Epub 2016 Nov 8.

PMID:
28068235
20.

Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

Applebaum MA, Vaksman Z, Lee SM, Hungate EA, Henderson TO, London WB, Pinto N, Volchenboum SL, Park JR, Naranjo A, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ.

Eur J Cancer. 2017 Feb;72:177-185. doi: 10.1016/j.ejca.2016.11.022. Epub 2016 Dec 26.

21.

A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers.

Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ.

Cancer Res. 2017 Feb 15;77(4):971-981. doi: 10.1158/0008-5472.CAN-15-2906. Epub 2016 Dec 6.

22.

Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.

von Allmen D, Davidoff AM, London WB, Van Ryn C, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP.

J Clin Oncol. 2017 Jan 10;35(2):208-216. Epub 2016 Nov 21.

23.

Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.

Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H.

PLoS One. 2016 Aug 11;11(8):e0161039. doi: 10.1371/journal.pone.0161039. eCollection 2016.

24.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

25.

Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database.

Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS.

Eur J Cancer. 2016 Sep;65:1-10. doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17.

PMID:
27434878
26.

MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of Dyskerin.

O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Purgato S, Yang C, Murray J, Russell AJ, Flemming CL, von Jonquieres G, Pickett HA, London WB, Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL.

Cancer Res. 2016 Jun 15;76(12):3604-17. doi: 10.1158/0008-5472.CAN-15-0879. Epub 2016 Apr 13.

27.

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center.

Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1275-1283. doi: 10.1016/j.bbmt.2016.04.004. Epub 2016 May 8.

28.

A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation.

Treister NS, London WB, Guo D, Malsch M, Verrill K, Brewer J, Margossian S, Duncan C.

Photomed Laser Surg. 2016 Apr;34(4):178-84. doi: 10.1089/pho.2015.4021. Epub 2016 Mar 16.

PMID:
26982624
29.

End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant.

Ullrich CK, Lehmann L, London WB, Guo D, Sridharan M, Koch R, Wolfe J.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1049-1055. doi: 10.1016/j.bbmt.2016.02.012. Epub 2016 Feb 20.

30.

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA.

JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print]

PMID:
26822149
31.

Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study.

Tubman VN, Marshall R, Jallah W, Guo D, Ma C, Ohene-Frempong K, London WB, Heeney MM.

Pediatr Blood Cancer. 2016 Apr;63(4):671-6. doi: 10.1002/pbc.25875. Epub 2016 Jan 6.

32.

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.

Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG.

Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28.

33.

Use and Effectiveness of Gonadotropin-Releasing Hormone Agonists for Prophylactic Menstrual Suppression in Postmenarchal Women Who Undergo Hematopoietic Cell Transplantation.

Poorvu PD, Barton SE, Duncan CN, London WB, Laufer MR, Lehmann LE, Marcus KJ.

J Pediatr Adolesc Gynecol. 2016 Jun;29(3):265-8. doi: 10.1016/j.jpag.2015.10.013. Epub 2015 Oct 23.

PMID:
26506031
34.

Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort Study.

Bona K, London WB, Guo D, Frank DA, Wolfe J.

Pediatr Blood Cancer. 2016 Jan;63(1):105-11. doi: 10.1002/pbc.25762. Epub 2015 Sep 23.

PMID:
26398865
35.

Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL.

J Clin Oncol. 2015 Sep 20;33(27):3008-17. doi: 10.1200/JCO.2014.59.4648. Epub 2015 Aug 24. Review.

36.

Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.

Mandriota SJ, Valentijn LJ, Lesne L, Betts DR, Marino D, Boudal-Khoshbeen M, London WB, Rougemont AL, Attiyeh EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F.

Oncotarget. 2015 Jul 30;6(21):18558-76.

37.

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H.

Br J Cancer. 2015 Jun 30;113(1):57-63. doi: 10.1038/bjc.2015.188. Epub 2015 Jun 2.

38.

SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.

Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, London WB, Matthay KK; International Society of Pediatric Oncology.

Pediatr Blood Cancer. 2015 Aug;62(8):1305-16. doi: 10.1002/pbc.25501. Epub 2015 Mar 21.

39.

Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation.

Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE.

Biol Blood Marrow Transplant. 2015 May;21(5):913-9. doi: 10.1016/j.bbmt.2015.01.027. Epub 2015 Feb 7.

40.

Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors.

Forester CM, Sartain SE, Guo D, Harris MH, Weinberg OK, Fleming MD, London WB, Williams DA, Hofmann I.

Am J Hematol. 2015 Apr;90(4):320-6. doi: 10.1002/ajh.23937. Epub 2015 Mar 2.

41.

ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP.

Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10.

42.

Voriconazole phototoxicity in children: a retrospective review.

Sheu J, Hawryluk EB, Guo D, London WB, Huang JT.

J Am Acad Dermatol. 2015 Feb;72(2):314-20. doi: 10.1016/j.jaad.2014.10.023. Epub 2014 Dec 3.

PMID:
25481710
43.

Prevalence and impact of financial hardship among New England pediatric stem cell transplantation families.

Bona K, London WB, Guo D, Abel G, Lehmann L, Wolfe J.

Biol Blood Marrow Transplant. 2015 Feb;21(2):312-8. doi: 10.1016/j.bbmt.2014.10.016. Epub 2014 Oct 23.

44.

Reply to N.-K.V. Cheung et al.

Matthay KK, London WB, Maris J, Adamson PC, Park JR.

J Clin Oncol. 2014 Dec 20;32(36):4174-5. doi: 10.1200/JCO.2014.58.7006. Epub 2014 Nov 17. No abstract available.

45.

Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.

Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, London WB, Chen L, de Alarcon P.

Pediatr Blood Cancer. 2015 Jan;62(1):60-4. doi: 10.1002/pbc.25205. Epub 2014 Oct 12. Erratum in: Pediatr Blood Cancer. 2015 May;62(5):927.

46.

A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.

Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D, Harris CE, Hopkins G, Lehmann LE, Lim A, London WB, van der Loo JC, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, Thrasher AJ.

N Engl J Med. 2014 Oct 9;371(15):1407-17. doi: 10.1056/NEJMoa1404588.

47.

Age-dependent prognostic effect by Mitosis-Karyorrhexis Index in neuroblastoma: a report from the Children's Oncology Group.

Teshiba R, Kawano S, Wang LL, He L, Naranjo A, London WB, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H.

Pediatr Dev Pathol. 2014 Nov-Dec;17(6):441-9. doi: 10.2350/14-06-1505-OA.1. Epub 2014 Sep 10.

48.

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG.

J Clin Oncol. 2014 Oct 1;32(28):3169-76. doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25.

49.

Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.

Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR.

Pediatr Blood Cancer. 2014 Nov;61(11):1932-9. doi: 10.1002/pbc.25134. Epub 2014 Jul 7.

PMID:
25044743
50.

Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.

Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T.

Oncotarget. 2014 Jun 30;5(12):4257-68.

Supplemental Content

Loading ...
Support Center